TrianglePembrolizumab (NCT06004336)
Pembrolizumab trial for Oligometastatic Renal Cell Carcinoma (NCT06004336). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with renal-cell cancer containing clear-cell features and up to five metastases. Measurable disease suitable for definitive radiation is required. Previous systemic therapy must meet treatment-specific washout periods.
The idea: after radiation treats tumor sites, pembrolizumab releases the PD1 immune brake. Randomization assigns one year of pembrolizumab or observation. Researchers compare cancer progression, survival, and safety. Biopsy is planned, with exceptions when biopsy poses undue risk; brain metastases can qualify.
This phase 2 study plans 144 patients. Chad Tang leads at MD Anderson, Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.